导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.70% | 2722/4773 |
| 近一周 | -2.17% | 1379/5462 |
| 近一月 | -4.13% | 2243/5421 |
| 近一季 | -7.42% | 2395/5209 |
| 近半年 | -2.67% | 1983/4920 |
| 近一年 | 0.83% | 2471/4366 |
| 近两年 | 44.83% | 1648/2954 |
| 近三年 | 27.63% | 1153/2253 |
| 成立以来 | 87.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.50% 3243/4961 |
12.20% 2208/5312 |
- - |
- - |
| 2025 | 19.77% 2181/4813 |
-0.94% 2480/3635 |
2.22% 1745/4076 |
18.02% 2364/4524 |
0.23% 2114/4813 |
| 2024 | 16.38% 817/3463 |
2.83% 691/2808 |
-1.06% 908/3014 |
16.23% 1504/3129 |
-1.58% 1756/3463 |
| 2023 | -8.68% 1047/2656 |
4.38% 966/2280 |
-3.79% 902/2385 |
-2.85% 769/2515 |
-6.40% 1754/2655 |
| 2022 | -18.96% 781/2207 |
-13.77% 834/1919 |
6.69% 631/2016 |
-13.56% 919/2113 |
1.91% 1089/2208 |
| 2021 | -2.43% 854/1822 |
-2.89% 721/1255 |
4.41% 891/1330 |
-5.35% 799/1466 |
1.66% 841/1822 |
| 2020 | 29.72% 531/1250 |
-9.21% 664/1028 |
13.31% 629/1067 |
11.40% 453/1164 |
13.19% 382/1184 |
| 2019 | 35.81% 368/1092 |
26.32% 413/754 |
-0.08% 213/804 |
0.69% 484/850 |
6.86% 531/918 |
| 2018 | -22.20% 232/834 |
- - |
- - |
- - |
-11.61% 326/691 |
| 2017 | 22.63% 145/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.04% 238/605 |
- - |
- - |
- - |
- - |
| 2015 | 6.73% 187/575 |
- - |
- - |
- - |
- - |
| 2014 | 50.93% 79/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.80% 104/186 |
- - |
- - |
- - |
- - |
| 2012 | 8.27% 57/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.02% 56/102 |
- - |
- - |
- - |
- - |
| 2010 | -11.85% 28/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达沪深300ETF联接A VS. 长安沪深300非周期A(740101) |